Beğen
Yorum Yap
Paylaş
Kapağı yeniden konumlandırmak için sürükleyin
Daha fazla Mesajları yükle
Yaklaşık
At LIQOMICS, we specialize in advanced minimal residual disease (MRD) testing using liquid biopsy techniques. Our ctDNA-based assays offer unparalleled sensitivity, enabling early detection of residual cancer cells post-treatment. This approach facilitates timely interventions and personalized treatment strategies. Trust LIQOMICS for precise MRD monitoring to enhance patient outcomes.
Avatarını kırp